LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Non-current Liabilities
All obligations due after more than one year.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 21.7% from a year ago
Total non-current liabilities stood at $3.88M at the end of Q1 FY2026, down 21.7% from a year earlier and down 7.1% from the prior quarter. Over 3 fiscal years it compounded at -56.2% a year.
Context
- Total non-current liabilities amounted to 1.0% of total assets at the end of Q1 FY2026, down 24.8 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -21.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.18M USD
- Year-over-year change
- -96.5%
- 3-year CAGR
- -56.2%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.18M | -96.5% |
| FY2024 | 2024-12-31 | 119.98M | +54.8% |
| FY2023 | 2023-12-31 | 77.52M | +55.6% |
| FY2022 | 2022-12-31 | 49.84M | — |
Total Non-current Liabilities vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total non-current liabilities of $3.88M is the 9th highest of the 10 companies compared; the peer median is $38.52M.
- Its year-over-year change of -21.7% is the 7th highest of 9, against a peer median of +7.0%.
- Total non-current liabilities amounts to 1.0% of total assets for LBRX, versus a peer median of 4.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $292.69B | +487717.0% | +47.5% | 307.8% | |
| Jun 2026 | $232.69M | +383.5% | -15.3% | 20.1% | |
| Sep 2026 | $74.45M | +30.8% | -1.1% | 4.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $53.08M | — | -59.9% | 34.5% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $38.52M | -5.8% | +226.1% | 3.6% |
| Mar 2026 | $19.78M | -22.6% | -35.7% | 7.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $8.19M | +19.8% | -5.8% | 1.6% |
| Mar 2026 | $4.67M | -16.4% | -6.1% | 1.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.88M | -21.7% | -56.2% | 1.0% |
| Mar 2026 | $75K | -76.7% | -57.1% | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $38.52M | +7.0% | -6.1% | 4.1% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.